To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 )
after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained
on a stable dose of zidovudine ( AZT ). To investigate the optimum dose regimen of U-90152
that gives average trough concentrations > 1 micromolar in combination with standard AZT
therapy, and to examine drug interactions between the two drugs. To establish the MTD of
U-90152 in HIV-1 positive patients on stable AZT therapy. To investigate comparative
pharmacokinetics between HIV-1 positive men and women.
- Inhaled pentamidine following completion of the inpatient pharmacokinetic portion of
Patients must have:
- HIV-1 infection.
- CD4 count 200 - 500 cells/mm3.
- Maintenance on AZT for at least 6 weeks.
- No active opportunistic infections.
- Ability to swallow numerous tablets without difficulty.
- Ability to have blood samples drawn.
Patients with the following symptoms or conditions are excluded:
- Acute medical problems, including opportunistic infections (such as active
cryptococcosis, pneumocystis carinii, herpes zoster, histoplasmosis, CMV) and
nonopportunistic diseases (liver and renal disease, orthostatic hypotension,
hypertension, progressive multifocal leukoencephalopathy, lymphoma, Kaposi's sarcoma,
or other malignancy).
- Clinically significant hypersensitivity to piperazine type drugs (Antepar, Stelazine,
- Negative EMIT drug screen or equivalent for drugs of abuse.
- Antiretroviral agents other than AZT.
- Primary or secondary prophylactic medications for opportunistic infections (inhaled
pentamidine is permitted following completion of the inpatient pharmacokinetic
portion of the study).
Patients with the following prior conditions are excluded:
- History of clinically significant nervous system or muscle disease, seizure disorder,
AIDS dementia, or psychotic disorder that might impair study compliance.
- History of clinically significant cardiovascular, renal, hepatic, cardiac, pulmonary,
endocrine, hematologic, vascular, or collagen disease.
- Prior U-87201E or other non-nucleoside reverse transcriptase inhibitors (nevirapine,
TIBO, L-drugs, and HEPT).
- Antiretroviral agents (other than AZT) or immunomodulating agents within 15 days
prior to study entry.
- Primary prophylactic drugs within 15 days prior to study entry.
- Any known enzyme-inducing drug or any enzyme-inhibiting agents, such as ketoconazole,
fluconazole, rifampin, isoniazid, and cimetidine, within 15 days prior to study
- Any investigational medication within 15 days prior to study entry. Unwilling to
comply with safer sex practices. Active substance abuse. Alcohol consumption during
the inpatient pharmacokinetic portion of the study.